A Peek At What Seelos Therapeutics Inc. (SEEL) Insiders Are Doing

Seelos Therapeutics Inc. (NASDAQ:SEEL) saw an upside of 1.23% to $2.29 after adding $0.03 on Wednesday. The 5-day average trading volume is 3,135,292 shares of the company’s common stock. It has gained $2.44 in the past week. An average of 6,163,533 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,501,377.

SEEL’s 1-month performance is 16.49% or $0.33 on its low of $1.83 reached on 09/20/21. The company’s shares have touched a 52-week low of $0.72 and high of $6.60, with the stock’s rally to the 52-week high happening on 04/27/21. YTD, SEEL has achieved 43.04% or $0.69. However, the current price is down -65.33%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

Seelos Therapeutics Inc. (SEEL) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector. The company’s PE ratio for the last five years has touched a high of 8.243 and a low of 1.029. SEEL stock has a beta of 2.82. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.40.

Seelos Therapeutics Inc.’s quick ratio for the period ended June 29 was 11.90, with the current ratio over the same period at 11.90 meaning that SEEL stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 66.67% to $30000.0, while revenue of $20000.0 was 33.33% off the previous quarter. Analysts expected SEEL to announce -$0.12 per share in earnings in its latest quarter, but it posted -$0.1, representing a 16.70% surprise. EBITDA for the quarter stood at more than -$6.2 million. SEEL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 7.61 million, with total debt at $71000.0. Shareholders hold equity totaling $102.31 million

Technical Picture

Let’s look briefly at Seelos Therapeutics Inc. (SEEL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 51.65% to suggest the stock is trending Neutral, with historical volatility in this time period at 48.21%.

The stock’s 5-day moving average is $2.27, reflecting a unch or $unch change from its current price. SEEL is currently trading +14.65% above its 20-day SMA, -30.37% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +8.61% and +31.98% respectively.

Stochastic %K and %D was 30.16% and 35.91% and the average true range (ATR) pointed at 0.17. The RSI (14) points at 52.15%, while the 14-day stochastic is at 28.28% with the period’s ATR at 0.18. The stock’s 9-day MACD Oscillator is pointing at -0.03 and -0.06 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Seelos Therapeutics Inc. (NASDAQ: SEEL), ROTH Capital upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for SEEL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate SEEL as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.

What is SEEL’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $6.00 and a high of $14.00, with their median price target at $9.00. Looking at these predictions, the average price target given by analysts is for Seelos Therapeutics Inc. (SEEL) stock is $9.50.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam